163 related articles for article (PubMed ID: 34161866)
1. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
2. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
Talarico C; D'Antona L; Scumaci D; Barone A; Gigliotti F; Fiumara CV; Dattilo V; Gallo E; Visca P; Ortuso F; Abbruzzese C; Botta L; Schenone S; Cuda G; Alcaro S; Bianco C; Lavia P; Paggi MG; Perrotti N; Amato R
Oncotarget; 2015 Nov; 6(35):37511-25. PubMed ID: 26462020
[TBL] [Abstract][Full Text] [Related]
3. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation.
D'Antona L; Amato R; Talarico C; Ortuso F; Menniti M; Dattilo V; Iuliano R; Gigliotti F; Artese A; Costa G; Schenone S; Musumeci F; Abbruzzese C; Botta L; Trapasso F; Alcaro S; Paggi MG; Perrotti N
Cell Physiol Biochem; 2015; 35(5):2006-18. PubMed ID: 25871776
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
[TBL] [Abstract][Full Text] [Related]
5. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.
Talarico C; Dattilo V; D'Antona L; Barone A; Amodio N; Belviso S; Musumeci F; Abbruzzese C; Bianco C; Trapasso F; Schenone S; Alcaro S; Ortuso F; Florio T; Paggi MG; Perrotti N; Amato R
Oncotarget; 2016 Mar; 7(13):15868-84. PubMed ID: 26908461
[TBL] [Abstract][Full Text] [Related]
6. Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma.
Wang J; Zhuo J; Tao Y; Xu S; Chen Z; Yang F; Ke Q; Xie H; Zheng S; Wang H; Xu X
Int J Nanomedicine; 2020; 15():6839-6854. PubMed ID: 32982236
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.
Tarocchi M; Polvani S; Peired AJ; Marroncini G; Calamante M; Ceni E; Rhodes D; Mello T; Pieraccini G; Quattrone A; Luchinat C; Galli A
J Hepatol; 2014 Nov; 61(5):1064-72. PubMed ID: 24862448
[TBL] [Abstract][Full Text] [Related]
8. The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells.
Conza D; Mirra P; Calì G; Tortora T; Insabato L; Fiory F; Schenone S; Amato R; Beguinot F; Perrotti N; Ulianich L
J Cell Physiol; 2017 Dec; 232(12):3735-3743. PubMed ID: 28177128
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
10. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
J Med Chem; 1983 May; 26(5):633-8. PubMed ID: 6221099
[TBL] [Abstract][Full Text] [Related]
11. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
[TBL] [Abstract][Full Text] [Related]
12. The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells.
Catalogna G; Talarico C; Dattilo V; Gangemi V; Calabria F; D'Antona L; Schenone S; Musumeci F; Bianco C; Perrotti N; Amato R; Cascini GL
Cell Physiol Biochem; 2017; 43(1):108-119. PubMed ID: 28848088
[TBL] [Abstract][Full Text] [Related]
13. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
[TBL] [Abstract][Full Text] [Related]
15. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
16. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
de Groot FM; Broxterman HJ; Adams HP; van Vliet A; Tesser GI; Elderkamp YW; Schraa AJ; Kok RJ; Molema G; Pinedo HM; Scheeren HW
Mol Cancer Ther; 2002 Sep; 1(11):901-11. PubMed ID: 12481411
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility.
Niethammer A; Gaedicke G; Lode HN; Wrasidlo W
Bioconjug Chem; 2001; 12(3):414-20. PubMed ID: 11353540
[TBL] [Abstract][Full Text] [Related]
20. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells.
Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z
Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
